CD274 and non-small cell lung carcinoma: Large-scale clinical trials, such as Keynote 189 (5), Keynote 407 (6), CheckMate-9LA (7) and IMPOWER150 (8), have established anti-PD-1/PD-L1 combined with chemotherapy therapy as the standard of care for advanced NSCLC patients lacking driver mutations.